Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7942475 | 1.00 | CYP3A4 (0.40) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL7945879 | 0.95 | CYP3A4 (0.42) | CYP3A4 | |
| SCHEMBL12765213 | 0.95 | CYP3A4 (0.42) | CYP3A4 | |
| SCHEMBL7945657 | 0.93 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL7935892 | 0.93 | CYP3A4 (0.33) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL7943885 | 0.92 | CYP3A4 (0.40) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL12726202 | 0.92 | CYP3A4 (0.40) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL1635971 | 0.90 | CYP3A4 (0.39) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL7946019 | 0.90 | CYP3A4 (0.39) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 | |
| SCHEMBL7946872 | 0.90 | CYP3A4 (0.39) | CYP3A4ADORA3CHRM1TBXA2RPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | CYP3A4 4436/4885ADORA3 4683/4885CHRM1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.